Directors' Long Term Incentive Scheme

RNS Number : 6213M

Futura Medical PLC

18 August 2011

 



For immediate release

18 August 2011

Futura Medical plc

("Futura" or "the Company")

Directors' Long Term Incentive Scheme

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that the issue of the CE mark for CSD500 on 8 August 2011 will trigger an award of 550,000 Phantom Option Units in accordance with the Company's Long Term Incentive Scheme ("LTIS") and as previously disclosed in the Company's annual report. 

Further details of this award will be given in due course and, in accordance with the LTIS, will be based on the Company's closing share price on the 8 August 2011.  The determination will take place as soon as practicable after the release of the Company's interim results for the six months ended 30 June 2011 to be reported on 27 September 2011 and the consequent expiry of the current close period. A further announcement will be made in due course.

Details of the LTIS are set out on the Company's website under Governance.

For any further information please contact:

Futura Medical plc
James Barder, Chief Executive	Tel: [phone]
mail to: [e-mail]	www.futuramedical.com
Nomura Code Securities Limited
Phil Walker / Giles Balleny	Tel:[phone]
For media enquiries please contact:
Buchanan Communications
Mark Court	Tel: [phone]

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

 

END

 

 

RDSLVLFFFVFZBBQ